Perspectives for antitumor vaccines application
- Authors: Nikolaeva I.E.1, Golderova A.S.1, Egorov A.N.1, Gotovtsev R.A.1, Troev I.P.1, Tayurskaya K.S.1
-
Affiliations:
- North-Eastern Federal University named after M.K. Ammosov
- Issue: Vol 27, No 5 (2022)
- Pages: 195-206
- Section: Reviews
- URL: https://journals.rcsi.science/1028-9984/article/view/249550
- DOI: https://doi.org/10.17816/onco569011
- ID: 249550
Cite item
Abstract
In this article, we reviewed the works devoted to one of the promising areas in the immunotherapy of oncological diseases — tumor-specific vaccines based on immunocompetent cells. The most promising, effective and safe methods of cellular vaccination against cancer are presented based on data from clinical trials for the period 2016–2023, which are sorted in the article by the origin of the active component into non-cellular (vaccines based on oncolytic viruses, bacteria, nucleic acids, peptides and in-situ) and cellular (dendritic, T-effector, natural killer cells) immunotherapeutic approaches. Cancer vaccines based on personalized neo-antigenic dendritic cells have promising anti-tumor effects in clinical practice. Dendritic-based vaccines have a number of advantages, one example being the ability to activate both innate and adaptive immunity, as well as to develop long-term immunological memory against recurrence of tumors. DCs are the most professional and consistent antigens and are more effective in activating resting T cells. The review provides the most up-to-date information on cancer vaccines, as well as an analysis of the types of cancer vaccines, using both local and international sources. The conclusion of this brief review is the wide variety of types of tumor-specific vaccines and their rapid improvement.
Full Text
##article.viewOnOriginalSite##About the authors
Irina E. Nikolaeva
North-Eastern Federal University named after M.K. Ammosov
Author for correspondence.
Email: dyimovochka1992@yandex.ru
ORCID iD: 0000-0002-8691-9303
SPIN-code: 2717-7453
Researcher, Laboratory of Medical Biotechnologies
Russian Federation, 36 Kulakovskogo street, 677027 YakutskAitalina S. Golderova
North-Eastern Federal University named after M.K. Ammosov
Email: hoto68@mail.ru
ORCID iD: 0000-0002-6739-9453
SPIN-code: 7868-9925
Scopus Author ID: 55323055100
ResearcherId: AAP-1638-2020
MD, Dr. Sci. (Med.), Professor
Russian Federation, 36 Kulakovskogo street, 677027 YakutskAndrey N. Egorov
North-Eastern Federal University named after M.K. Ammosov
Email: 291219942014@mail.ru
ORCID iD: 0000-0003-4610-7105
SPIN-code: 7387-3990
postgraduate student, research engineer, laboratory of medical biotechnologies
Russian Federation, 36 Kulakovskogo street, 677027 YakutskRadomir A. Gotovtsev
North-Eastern Federal University named after M.K. Ammosov
Email: radomirgotovtsev@gmail.com
ORCID iD: 0009-0003-6978-3939
SPIN-code: 3195-6682
Scopus Author ID: 0009-0003-6978-3939
master's student
Russian Federation, 36 Kulakovskogo street, 677027 YakutskIvan P. Troev
North-Eastern Federal University named after M.K. Ammosov
Email: ysumed@yandex.ru
ORCID iD: 0000-0001-9782-8565
SPIN-code: 3750-7480
Senior Researcher, Laboratory of Medical Biotechnologies
Russian Federation, 36 Kulakovskogo street, 677027 YakutskKseniya S. Tayurskaya
North-Eastern Federal University named after M.K. Ammosov
Email: eilovi@yandex.ru
ORCID iD: 0009-0001-0218-817X
SPIN-code: 1967-5411
Research Engineer, Laboratory of Medical Biotechnology
Russian Federation, 36 Kulakovskogo street, 677027 YakutskReferences
- Liu J, Fu M, Wang M, et al. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. Journal of Hematology & Oncology. 2022;15:28. doi: 10.1186/s13045-022-01247-x
- Fritah H, Rovelli R, Chiang CL, Kandalaft LE. The current clinical landscape of personalized cancer vaccines. Cancer Treatment Reviews. 2022;106. doi: 10.1016/j.ctrv.2022.102383
- Goyvaerts C, Breckpot K. Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines. J Immunol Res. 2015;2015. doi: 10.1155/2015/785634
- Bastin DJ, Montroy J, Kennedy MA, et al. Safety and efficacy of autologous cell vaccines in solid tumors: a systematic review and meta-analysis of randomized control trials. Scientific reports. 2023;13:1–13. doi: 10.1038/s41598-023-29630-9
- Moiseenko VM. Vozmozhnosti vaktsinoterapii melanomy kozhi. Practical oncology. 2001;4(8):58–64. (In Russ).
- Feola S, Russo S, Martins B, et al. Peptides-Coated Oncolytic Vaccines for Cancer Personalized. Medicine. Frontiers in Immunology. 2022;13. doi: 10.3389/fimmu.2022.826164
- Hemminki О, Dos Santos JM, Hemminki A. Oncolytic viruses for cancer immunotherapy. Journal of Hematology & Oncology. 2020;13. doi: 10.1186/s13045-020-00922-1
- Mondal M, Guo J, He P, et al. Recent advances of oncolytic virus in cancer therapy. Human Vaccines & Immunotherapeutics. 2020;16(10):1–14. doi: 10.1080/21645515.2020.1723363
- Omid H, Rubina I, Puzanov I. Intratumoral Immunotherapy-Update 2019. The Oncologist. 2020;25(3):423–438. doi: 10.1634/theoncologist.2019-0438
- Ferrucci PF, Pala L, Conforti F, et al. Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers. 2021;13(6). doi: 10.3390/cancers13061383
- Robinson C, Xu MM, Nair SK, et al. Oncolytic viruses in melanoma. Front Biosci. 2022;27(2):63. doi: 10.31083/j.fbl2702063
- Forbes N. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer. 2010;10:785–794. doi: 10.1038/nrc2934
- Chen L, Qin H, Zhao R, et al. Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines. Sci Transl Med. 2021;13(601). doi: 10.1126/scitranslmed.abc2816
- Yu X, Lin C, Yu J, et al. Bioengineered Escherichia coli Nissle 1917 for tumour-targeting therapy. Microbial Biotechnology. 2019;13(3):629–636. doi: 10.1111/1751-7915.13523
- Toso JF, Gill VJ, Hwu P, et al. Phase I Study of the Intravenous Administration of Attenuated Salmonella typhimurium to Patients with Metastatic Melanoma. Journal of Clinical Oncology. 2002;20(1):142–152. doi: 10.1200/JCO.20.1.142
- Chen W, Wang Y, Qin M, et al. Bacteria-Driven Hypoxia Targeting for Combined Biotherapy and Photothermal Therapy. ACS Nano. 2018;12(6):5995–6005. doi: 10.1021/acsnano.8b02235
- Agrawal N, Bettegowda C, Cheong I, et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci USA. 2004;101(42):15172–15177. doi: 10.1073/pnas.0406242101
- Lobo N, Brooks NA, Zlotta AR, et al. 100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19. Nat Rev Urol. 2021;18:611–622. doi: 10.1038/s41585-021-00481-1
- Larsen ES, Joensen UN, Poulsen AM, et al. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections. APMIS. 2020;128(2):92–103. doi: 10.1111/apm.13011
- Cardillo F, Bonfim M, da Silva Vasconcelos Sousa P, et al. Bacillus Calmette-Guérin Immunotherapy for Cancer. Vaccines (Basel). 2021;9(5):1–15. doi: 10.3390/vaccines9050439
- Vandeborne L, Pantziarka P, Nuffel V, et al. Repurposing Infectious Diseases Vaccines Against Cancer. Frontiers in Oncology. 2021;11:120. doi: 10.3389/fonc.2021.688755
- Giaccone G, Debruyne C, Felip E, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer. Journal of Clinical Oncology. 2005;23(28):6854-6864. doi: 10.1200/JCO.2005.17.18
- Ylösmäki E, Fusciello M, Martins B, et al. Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin. The Journal for ImmunoTherapy of Cancer. 2021;9(7):1–13. doi: 10.1136/jitc-2021-002707
- Hager S, Fittler FJ, Wagner E, Bros M. Nucleic Acid-Based Approaches for Tumor Therapy. Cells. 2020;9(9):1–53. doi: 10.3390/cells9092061
- Jahanafrooz Z, Baradaran B, Mosafer J, et al. Comparison of DNA and mRNA vaccines against cancer. Drug Discov Today. 2020;25(3):552–560. doi: 10.1016/j.drudis.2019.12.003
- Baldueva IA. Protivoopukholevye vaktsiny. Practical oncology. 2003;4:157–166. (In Russ).
- Dyukalova MB. Development of peptide vaccines for active immunotherapy of breast cancer associated with HER-2 oncoprotein hyperproduction. Vestnik RONTs im. N.N. Blokhina RAMN. 2012;23(1):19–26. (In Russ).
- Hueman MT, Dehqanzada ZA, Novak TE, et al. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clinical Cancer Research. 2005;11:7470–7479. doi: 10.1158/1078-0432.CCR-05-0235
- Ramanathan RK, Lee KM, McKolanis J, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunology, Immunotherapy. 2005;54:254–264. doi: 10.1007/s00262-004-0581-1
- Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012;76:138–143. doi: 10.1016/j.lungcan.2011.11.012
- Akhtar NH, Pail O, Saran A, Tyrell L, Tagawa ST. Prostate-specific membrane antigen-based therapeutics. Advances in Urology. 2012;2012:9. doi: 10.1155/2012/973820
- Hammerich L, Binder A, Brody JD. In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf. Molecular Oncology. 2015;9(10):1966–1981. doi: 10.1016/j.molonc.2015.10.016
- Zinchenko AI, Shchekolova AS, Birichevskaya LL. In situ antitumor vaccination. In: Kolomiets EI, Lobanok AG, editors. Microbial biotechnologies: fundamental and applied aspects: Collection of scientific papers. Volume 10. Minsk: Belarusian Science; 2018. (In Russ).
- Okada H, Takahashi K, Yaku H, et al. In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy. Scientific Reports. 2022;12:2132. doi: 10.1038/s41598-022-05702-0
- Bouzid R, Peppelenbosch M, Buschow S. Opportunities for Conventional and In Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers. Cancers. 2020;12(5):1121. doi: 10.3390/cancers12051121
- Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nature Reviews Cancer. 2012;12(4):265–277. doi: 10.1038/nrc3258
- Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Annals of Oncology. 2006;17(4):563–570. doi: 10.1093/annonc/mdj138
- Nair SK, Morse M, Boczkowski D, et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Annals of Surgery. 2002;235(3):540–549. doi: 10.1097/00000658-200203000-00026
- Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England Journal of Medicine. 2010;363(5):411–422. doi: 10.1056/NEJMoa1001294
- Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15(7):e257–267. doi: 10.1016/S1470-2045(13)70585-0
- Al Saihati HA. Overview of Dendritic Cell Vaccines as Effective Approaches in Cancer Immunotherapy. Bahrain Medical Bulletin. 2021;43:737–746.
- Gu YZ, Zhao X, Song XR. Ex vivo pulsed dendritic cell vaccination against cancer. Acta Pharmacol Sin. 2020;41:959–969. doi: 10.1038/s41401-020-0415-5
- Baldueva IA, Nekhaeva TP, Protsenko SA, et al. Dendritic cell vaccines in immunotherapy of patients with solid tumors: textbook for doctors and students in the system of higher and additional professional education. Saint Petersburg; 2020. (In Russ).
- Duarte A. da S.S., Zangirolami AB, Santos I, et.al. Production of dendritic cell vaccines using different methods with equivalent results: Implications for emerging centers. Hematology, Transfusion and Cell Therapy. 2022;1379(22):1–6. doi: 10.1016/j.htct.2022.11.006
- Abdi K, Thomas LM, Laky K, et al. Bone Marrow–Derived Dendritic Cell Cultures from RAG−/− Mice Include IFN-γ–Producing NK Cells. Immunohorizons. 2020;4(7):415–419. doi: 10.4049/immunohorizons.2000011
- Pham V, Nguyen S, Pham P. Production of functional dendritic cells from mouse bone marrow. Biomedical Research and Therapy. 2014;1(4):126–132.
- Kumar J, Kale V, Limaye L. Umbilical cord blood-derived CD11c+ dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy. Stem Cell Res Ther. 2015;6:184. doi: 10.1186/s13287-015-0160-8
- Mu Y, Wang W, Xie J, et al. Efficacy and safety of cord blood-derived dendritic cells plus cytokine-induced killer cells combined with chemotherapy in the treatment of patients with advanced gastric cancer: a randomized Phase II study. Onco Targets Ther. 2016;9:4617–4627. doi: 10.2147/OTT.S107745
- de Haar C, Plantinga M, Blokland NJ, et al. Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation. Oncoimmunology. 2015;4(11):e1023973. doi: 10.1080/2162402X
- Mackall CL, Rhee EH, Read EJ, et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clinical Cancer Research. 2008;14(15):4850–4858. doi: 10.1158/1078-0432.CCR-07-4065
- Chia WK, Teo M, Wang WW, et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Molecular Therapy. 2014;22(1):132–139. doi: 10.1038/mt.2013.242
- Laetsch TW, Maude SL, Balduzzi A, et al. Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia. Leukemia. 2022;36:1508–1515. doi: 10.1038/s41375-022-01550-z
- Manickam C, Sugawara S, Reeves RK. Friends or foes? The knowns and unknowns of natural killer cell biology in COVID-19 and other coronaviruses in July 2020. PLOS Pathogens. 2020;16(8):e1008820. doi: 10.1371/journal.ppat.1008820
- Chu J, Gao F, Yan M, et al. Natural killer cells: a promising immunotherapy for cancer. Journal of Translational Medicine. 2022;20:240. doi: 10.1186/s12967-022-03437-0
- Sakamoto N, Ishikawa T, Kokura S, et al. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. Journal of Translational Medicine. 2015;13:277. doi: 10.1186/s12967-015-0632-8
- Feifeng W, Min X, Marady H, et al. Natural Killer Cell-Derived Extracellular Vesicles: Novel Players in Cancer Immunotherapy. Frontiers in Immunology. 2021;12. doi: 10.3389/fimmu.2021.658698
- Clinicaltrials.gov [Internet]. Rockville (MD): Clinical research studies and information about their results. C2000 — [cited 2023 Jun 21]. Available from: https://clinicaltrials.gov